Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

8.640 -0.310 (-3.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Immunome Inc. (NASDAQ: IMNM) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
Via Spotlight Growth
Why Are Immunome Shares Trading Higher Today
Immunome Inc (NASDAQ: IMNM) and Morphimmune have announced a merger agreement in  
Via Benzinga
Immunome: Q1 Earnings Insights
Via Benzinga
Immunome Stock Jumps On Discovery Pact With AbbVie
Via Benzinga
Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants
Via Benzinga
Dow Rises Over 100 Points; US GDP Grows 2% In Q1
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.37% to 33,977.04 while the NASDAQ rose... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
From Immunome
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome to Present at 13th Annual World ADC London Conference
From Immunome, Inc.
Via Business Wire
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
From Immunome, Inc.
Via Business Wire
AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal
AbbVie is tapping Immunome to help develop new cancer treatments. 
Via Investor's Business Daily
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
From Immunome, Inc.
Via Business Wire
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Immunome Reports Third Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
Gainers Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115. 
Via Benzinga
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Immunome, Inc.
Via Business Wire
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
From Immunome, Inc.
Via Business Wire
Recap: Immunome Q2 Earnings
Immunome (NASDAQ:IMNM) reported its Q2 earnings results on Friday, August 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Immunome beat estimated earnings by... 
Via Benzinga
Immunome Reports Second Quarter 2022 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
From Immunome, Inc.
Via Business Wire
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.